BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23243217)

  • 1. Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer.
    Siemens H; Neumann J; Jackstadt R; Mansmann U; Horst D; Kirchner T; Hermeking H
    Clin Cancer Res; 2013 Feb; 19(3):710-20. PubMed ID: 23243217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between miR-34 dysregulation and distant metastases formation in lung adenocarcinoma.
    Daugaard I; Knudsen A; Kjeldsen TE; Hager H; Hansen LL
    Exp Mol Pathol; 2017 Jun; 102(3):484-491. PubMed ID: 28512015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
    Vogt M; Munding J; Grüner M; Liffers ST; Verdoodt B; Hauk J; Steinstraesser L; Tannapfel A; Hermeking H
    Virchows Arch; 2011 Mar; 458(3):313-22. PubMed ID: 21225432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Methylation of the p53 Targets the Genes
    Voropaeva EN; Pospelova TI; Orlov YL; Churkina MI; Berezina OV; Gurazheva AA; Ageeva TA; Seregina OB; Maksimov VN
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal Cancer.
    Shi X; Kaller M; Rokavec M; Kirchner T; Horst D; Hermeking H
    Cell Mol Gastroenterol Hepatol; 2020; 10(2):391-418. PubMed ID: 32304779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In bone metastasis miR-34a-5p absence inversely correlates with Met expression, while Met oncogene is unaffected by miR-34a-5p in non-metastatic and metastatic breast carcinomas.
    Maroni P; Puglisi R; Mattia G; Carè A; Matteucci E; Bendinelli P; Desiderio MA
    Carcinogenesis; 2017 May; 38(5):492-503. PubMed ID: 28334277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic inactivation of DAPK1, p14ARF, mir-34a and -34b/c in acute promyelocytic leukaemia.
    Ng HY; Wan TS; So CC; Chim CS
    J Clin Pathol; 2014 Jul; 67(7):626-31. PubMed ID: 24811488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer.
    Wu XD; Song YC; Cao PL; Zhang H; Guo Q; Yan R; Diao DM; Cheng Y; Dang CX
    Med Oncol; 2014 Apr; 31(4):894. PubMed ID: 24573638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients.
    Hong JH; Roh KS; Suh SS; Lee S; Sung SW; Park JK; Byun JH; Kang JH
    Tumour Biol; 2015 Dec; 36(12):9327-37. PubMed ID: 26104764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer.
    Hiyoshi Y; Schetter AJ; Okayama H; Inamura K; Anami K; Nguyen GH; Horikawa I; Hawkes JE; Bowman ED; Leung SY; Harris CC
    PLoS One; 2015; 10(4):e0124899. PubMed ID: 25894979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer.
    Xie K; Liu J; Chen J; Dong J; Ma H; Liu Y; Hu Z
    Gene; 2014 Jun; 543(1):101-7. PubMed ID: 24704024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of miR-34a contributes to the risk, progression, metastasis and poor survival of laryngeal squamous cell carcinoma.
    Shen Z; Zhou C; Li J; Ye D; Li Q; Wang J; Cui X; Chen X; Bao T; Duan S
    Gene; 2016 Nov; 593(2):272-6. PubMed ID: 27450916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer.
    Gallardo E; Navarro A; Viñolas N; Marrades RM; Diaz T; Gel B; Quera A; Bandres E; Garcia-Foncillas J; Ramirez J; Monzo M
    Carcinogenesis; 2009 Nov; 30(11):1903-9. PubMed ID: 19736307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent downregulation of miR-34 family in human ovarian cancers.
    Corney DC; Hwang CI; Matoso A; Vogt M; Flesken-Nikitin A; Godwin AK; Kamat AA; Sood AK; Ellenson LH; Hermeking H; Nikitin AY
    Clin Cancer Res; 2010 Feb; 16(4):1119-28. PubMed ID: 20145172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNA XIST sponges miR-34a to promotes colon cancer progression via Wnt/β-catenin signaling pathway.
    Sun N; Zhang G; Liu Y
    Gene; 2018 Jul; 665():141-148. PubMed ID: 29679755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer.
    Wang Z; Chen Z; Gao Y; Li N; Li B; Tan F; Tan X; Lu N; Sun Y; Sun J; Sun N; He J
    Cancer Biol Ther; 2011 Mar; 11(5):490-6. PubMed ID: 21383543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
    Schmid G; Notaro S; Reimer D; Abdel-Azim S; Duggan-Peer M; Holly J; Fiegl H; Rössler J; Wiedemair A; Concin N; Altevogt P; Marth C; Zeimet AG
    BMC Cancer; 2016 Feb; 16():102. PubMed ID: 26879132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.
    Lodygin D; Tarasov V; Epanchintsev A; Berking C; Knyazeva T; Körner H; Knyazev P; Diebold J; Hermeking H
    Cell Cycle; 2008 Aug; 7(16):2591-600. PubMed ID: 18719384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition.
    Hahn S; Jackstadt R; Siemens H; Hünten S; Hermeking H
    EMBO J; 2013 Nov; 32(23):3079-95. PubMed ID: 24185900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma.
    Cui X; Zhao Z; Liu D; Guo T; Li S; Hu J; Liu C; Yang L; Cao Y; Jiang J; Liang W; Liu W; Li S; Wang L; Wang L; Gu W; Wu C; Chen Y; Li F
    J Exp Clin Cancer Res; 2014 Feb; 33(1):20. PubMed ID: 24528540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.